A phase 4 single-arm open-label clinical study of pembrolizumab (MK-3475) to evaluate the efficacy and safety of MK-3475 plus carboplatin and paclitaxel as first-line treatment of recurrent/ metastatic head and neck squamous cell carcinoma.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.